Ascendis moves forward with phase III drug

Ascendis Pharma has now reached the desired amount of patients for its phase III trial for the rare disease hypoparathyreoidism. The company has also achieved regulatory progress for the same drug in Japan.

Photo: Kevin Grønnemann

Ascendis Pharma can be satisfied with the progress it has made on several fronts regarding its new drug candidate.

The Danish, but US-listed, biotech company reports that it has recruited the required amount of patients for the company's phase III trial with the drug palopegteriparatide, also known as Transcon PTH, for the disease hypoparathyreoidism. The firm is also willing to let in patients who were prepped for the study in June, if they meet the required criteria.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs